FDA Pre-Submission (Q-Sub) is a voluntary request that lets a medical device sponsor obtain written feedback or a meeting with the FDA before filing a marketing application. Submitted under the agency’s Q-Submission Program, it clarifies regulatory strategy, testing plans, and study design early, reducing the risk of deficiencies during formal review.
What is FDA Pre-Submission (Q-Sub)?
The FDA Pre-Submission, commonly called a Pre-Sub, is the most used pathway within the FDA’s Q-Submission (Q-Sub) Program. The program gives device sponsors a structured way to ask the Center for Devices and Radiological Health (CDRH) or the Center for Biologics Evaluation and Research (CBER) specific questions outside a formal submission. A Pre-Sub sits in the early planning stage of the device lifecycle, usually before design verification is complete and well before a 510(k), De Novo, PMA, HDE, or IDE application is assembled.
The program began in 1995 as the Pre-IDE Program, expanded under FDASIA in 2012, and now covers several interaction types: Pre-Submissions, Submission Issue Requests, Study Risk Determinations, and Informational Meetings. The current final guidance, “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program,” was issued in May 2025 and replaced the 2023 version.
Why FDA Pre-Submission matters in medical device development
Getting FDA input before you file changes the economics of a program. A single review cycle can add months, and a rejected submission means repeating tests, rewriting protocols, or redesigning a device that already passed verification. A Pre-Sub lets a team confirm its predicate choice, classification, and test plan while changes are still cheap.
There is no user fee for a Q-Sub, so the main cost is preparation time. For a startup burning runway, or an OEM with a fixed launch window, that trade is easy to justify. Early alignment on human factors, biocompatibility, or clinical evidence expectations also lowers audit and rework exposure later, since the eventual submission reflects positions the review division has already seen.
How the FDA Pre-Submission (Q-Sub) process works
A Pre-Sub is a written package sent to the relevant FDA review division. A well-formed request generally includes:
- A cover letter naming the Q-Sub type and the intended submission it supports.
- A device description covering intended use and technological characteristics.
- Background on development status and any prior FDA interaction.
- A focused set of questions, ideally five or six, each specific enough to answer.
- The feedback format requested: written responses, a teleconference, or a meeting.
After receipt, FDA confirms the request and, for a Pre-Sub, generally provides written feedback or holds the meeting within about 70 to 75 calendar days. Questions should map to real decision points: predicate strategy, proposed bench testing against recognized consensus standards, animal or clinical study design, or software documentation under IEC 62304. Vague or overly broad questions are the most common reason the FDA declines to accept a package.
Feedback reflects the agency’s current thinking, not a binding decision or a promise of clearance. If more than a year passes without initiating the discussed study, sponsors should confirm with the division that the earlier feedback still holds.
Common challenges and best practices
The frequent mistake is treating a Pre-Sub as a broad conversation rather than a set of decisions. Open-ended questions like “Is our approach acceptable?” produce vague answers. Sharp questions that state your proposed position and ask the FDA to agree or object produce usable ones.
Timing matters too. Send a Pre-Sub too early, before you have a device description and a draft test plan, and there is little for the FDA to react to. Send it too late, after verification is locked, and the feedback arrives when changes are expensive. Aim for the point where your strategy is concrete but still adjustable. Keep the question count small, tie each question to a standard or regulation by number, and record how you will act on the feedback in the eventual submission.
How SJML helps with FDA Pre-Submission (Q-Sub)
SJML’s QARA team supports Q-Submission planning as part of its Compliance-as-a-Service model. That work includes device classification, predicate and regulatory strategy, and preparing the questions and supporting documentation that make FDA feedback useful. The same team handles downstream FDA 510(k), De Novo, and PMA pathways, so positions raised in a Pre-Sub carry through to the eventual submission and technical file. For OEMs and startups without in-house regulatory depth, this early alignment shortens the path to a defensible marketing application.
Frequently asked questions
No. The Q-Submission Program, including Pre-Submissions, carries no user fee. The program is voluntary, and the only real cost to a sponsor is the internal time spent preparing a clear request and set of questions. This keeps early FDA engagement accessible even to small companies and first-time submitters planning a 510(k), De Novo, or PMA.
For a Pre-Submission, FDA generally provides written feedback or holds the requested meeting within about 70 to 75 calendar days of receipt. The agency first confirms the request and assesses whether it fits the program. Building this window into your development timeline prevents the feedback from arriving after key design decisions are already locked.
No. Feedback represents FDA’s current thinking based on the information you provided, not a guarantee of clearance or approval. The agency can revise its position when it reviews the actual submission, especially if the device, data, or applicable standards change. Even so, documented alignment on major questions carries real weight and reduces the chance of surprise deficiencies.
Submit when your regulatory strategy is concrete enough to ask specific questions but flexible enough to act on the answers. That usually means you have an intended use, a device description, a proposed classification, and a draft test plan, but have not yet locked in design verification. This timing lets FDA feedback shape testing and study design while changes remain inexpensive.
Related terms
- 510(k) Submission
- De Novo Classification Request
- Investigational Device Exemption (IDE)
- Design Verification
- Regulatory Strategy
